Pd(II) and Pt(II) complexes with the anions of the model nucleobases 1-methylthymine (1-MethyH), 1-methyluracil (1-MeuraH), and 1-methylcytosine (1-MecytH) of the types [Pd(dmba)(μ-L)]2 [dmba = N,C-chelating 2-((dimethyl-amino)methyl)phenyl; L = 1-Methy, 1-Meura or 1-Mecyt] and [M(dmba)(L)(L′)] [L = 1-Methy or 1-Meura; L′ = PPh3 (M = Pd or Pt), DMSO (M = Pt)] have been obtained. Palladium complexes of the types [Pd(C6F5)(N-N)(L)] [L = 1-Methy or 1-Meura; N-N = N,N,N′,N′-tetramethylethylenediamine (tmeda), 2,2′-bipyridine (bpy), or 4,4′-dimethyl-2,2′-bipyridine (Me2bpy)] and [NBu4][Pd(C6F5)(1-Methy)2(H 2O)] have also been prepared. The crystal structures of [Pd(dmba)(μ-1-Methy)]2, [Pd(dmba)(μ-1-Mecyt)] 2·2CHCl3, [Pd(dmba)(1-Methy)(PPh 3)]·3CHCl3, [Pt(dmba)(1-Methy)(PPh3)], [Pd(tmeda)(C6F5)(1-Methy)], and [NBu4] [Pd(C6F5)(1-Methy)2(H2O)] ·H2O have been established by X-ray diffraction. The DNA adduct formation of the new platinum complexes synthesized was followed by circular dichroism and electrophoretic mobility. Atomic force microscopy images of the modifications caused by the platinum complexes on plasmid DNA pBR322 were also obtained. Values of IC50 were also calculated for the new platinum complexes against the tumor cell line HL-60. All the new platinum complexes were more active than cisplatin (up to 20-fold in some cases). © 2006 American Chemical Society.